Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Revenue (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Revenue for 7 consecutive years, with $321.1 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 210.77% to $321.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $958.4 million through Dec 2025, up 432.05% year-over-year, with the annual reading at $958.4 million for FY2025, 432.05% up from the prior year.
  • Revenue for Q4 2025 was $321.1 million at Madrigal Pharmaceuticals, up from $287.3 million in the prior quarter.
  • The five-year high for Revenue was $321.1 million in Q4 2025, with the low at $14.6 million in Q2 2024.